Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 1,850,000 shares, a decline of 6.6% from the May 31st total of 1,980,000 shares. Currently, 7.7% of the shares of the company are short sold. Based on an average trading volume of 233,700 shares, the short-interest ratio is presently 7.9 days.
Bolt Biotherapeutics Stock Performance
NASDAQ BOLT opened at $0.74 on Thursday. The company has a quick ratio of 5.68, a current ratio of 5.68 and a debt-to-equity ratio of 0.16. Bolt Biotherapeutics has a twelve month low of $0.72 and a twelve month high of $1.56. The business has a 50-day moving average price of $0.87 and a 200-day moving average price of $1.06. The firm has a market cap of $28.03 million, a price-to-earnings ratio of -0.44 and a beta of 0.94.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.23. Bolt Biotherapeutics had a negative return on equity of 51.74% and a negative net margin of 556.59%. The company had revenue of $5.27 million for the quarter, compared to analysts’ expectations of $2.63 million. As a group, equities research analysts predict that Bolt Biotherapeutics will post -1.4 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Analysis on BOLT
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.
Featured Stories
- Five stocks we like better than Bolt Biotherapeutics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Celebrate July 4th with These Red, White, & Blue Chip Stocks
- What Does a Stock Split Mean?
- AbbVie Stock: A Perfect Dip for Investors to Buy
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.